Contrasting Stemline Therapeutics (STML) and Its Peers

Stemline Therapeutics (NASDAQ: STML) is one of 287 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Stemline Therapeutics to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, dividends, institutional ownership and earnings.

Volatility and Risk

Stemline Therapeutics has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. Comparatively, Stemline Therapeutics’ peers have a beta of 2.38, suggesting that their average share price is 138% more volatile than the S&P 500.

Valuation & Earnings

This table compares Stemline Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Stemline Therapeutics $1.04 million -$38.30 million -5.91
Stemline Therapeutics Competitors $290.27 million $35.99 million 57.55

Stemline Therapeutics’ peers have higher revenue and earnings than Stemline Therapeutics. Stemline Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

50.2% of Stemline Therapeutics shares are held by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.7% of Stemline Therapeutics shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Stemline Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Stemline Therapeutics -4,689.63% -75.50% -64.20%
Stemline Therapeutics Competitors -5,441.68% -162.70% -35.92%

Analyst Ratings

This is a breakdown of current ratings and target prices for Stemline Therapeutics and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stemline Therapeutics 0 0 5 0 3.00
Stemline Therapeutics Competitors 925 3347 11854 237 2.70

Stemline Therapeutics presently has a consensus price target of $33.75, indicating a potential upside of 122.04%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.73%. Given Stemline Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Stemline Therapeutics is more favorable than its peers.

Summary

Stemline Therapeutics peers beat Stemline Therapeutics on 7 of the 13 factors compared.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply